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The microglial activation state regulates
migration and roles of matrix-dissolving
enzymes for invasion
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Abstract
Background: Microglial cells are highly mobile under many circumstances and, after central nervous system (CNS)
damage, they must contend with the dense extracellular matrix (ECM) in order to reach their target sites. In
response to damage or disease, microglia undergo complex activation processes that can be modulated by
environmental cues and culminate in either detrimental or beneficial outcomes. Thus, there is considerable interest
in comparing their pro-inflammatory (‘classical’ activation) and resolving ‘alternative’ activation states. Almost
nothing is known about how these activation states affect the ability of microglia to migrate and degrade ECM,
or the enzymes used for substrate degradation. This is the subject of the present study.
Methods: Primary cultured rat microglial cells were exposed to lipopolysaccharide (LPS) to evoke classical activation
or IL4 to evoke alternative activation. High-resolution microscopy was used to monitor changes in cell morphology
and aspects of the cytoskeleton. We quantified migration in a scratch-wound assay and through open filter holes,
and invasion through Matrigel™. A panel of inhibitors was used to analyze contributions of different matrix-
degrading enzymes to migration and invasion, and quantitative real-time reverse transcriptase PCR (qRT-PCR) was
used to assess changes in their expression.
Results: Vinculin- and F-actin-rich lamellae were prominent in untreated and IL4-treated microglia (but not after
LPS). IL4 increased the migratory capacity of microglia but eliminated the preferential anterior nuclear-centrosomal
axis polarity and location of the microtubule organizing center (MTOC). Microglia degraded fibronectin, regardless
of treatment, but LPS-treated cells were relatively immobile and IL4-treated cells invaded much more effectively
through Matrigel™. For invasion, untreated microglia primarily used cysteine proteases, but IL4-treated cells used a
wider range of enzymes (cysteine proteases, cathepsin S and K, heparanase, and matrix metalloproteases).
Untreated microglia expressed MMP2, MMP12, heparanase, and four cathepsins (B, K, L1, and S). Each activation
stimulus upregulated a different subset of enzymes. IL4 increased MMP2 and cathepsins S and K; whereas LPS
increased MMP9, MMP12, MMP14 (MT1-MMP), heparanase, and cathepsin L1.
Conclusions: Microglial cells migrate during CNS development and after CNS damage or disease. Thus, there are
broad implications of the finding that classically and alternatively activated microglia differ in morphology,
cytoskeleton, migratory and invasive capacity, and in the usage of ECM-degrading enzymes.
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Introduction
In the healthy adult brain, microglial cells continually
extend and retract their ramified processes without over-
all cell displacement [1]. However, in the uninjured
brain, microglia are highly migratory during the peri-
natal period of development. After central nervous sys-
tem (CNS) injury in the adult, microglia retract their
processes, adopt an amoeboid shape, and can migrate
over relatively long distances to accumulate at damage
sites [2,3]). In general, when cells migrate on a two-
dimensional (2-D) substrate, they are polarized along the
axis of movement, with a fan-shaped lamella bearing
thin F-actin-rich protrusions (lamellipodia, filopodia) at
the leading edge [4]. The forward-propelling machinery
for cell migration requires turnover of substrate adhe-
sions - with disassembly at the rear and re-assembly in
newly protruded sites - while cell invasion through tis-
sue also requires dissolution of the extracellular matrix
(ECM).
When microglia respond to CNS damage or disease, it
is expected that their activation mechanisms and out-
comes will depend on the type of injury and stimuli en-
countered, for example, sterile versus non-sterile
inflammation [5,6]. Part of the ongoing controversy
about whether microglial activation is harmful or helpful
in the damaged or diseased CNS [7,8] derives from their
potential to exist in multiple activation states [6,9]. Until
recently, models of microglial activation were based on
macrophage activation, which was often simplified to
classical (‘M1’) activation, evoked by exposure to
interferon-γ or bacterial toxins (for example, lipopoly-
saccharide, LPS), and alternative activation (‘M2’), which
is evoked by interleukin (IL)4 or IL13 [10-12]. Based on
in vitro studies of microglia [13-17], it is clear that LPS
can upregulate pro-inflammatory cytokines (for example,
IL1β, tumor necrosis factor-α), excitatory amino acids,
proteases, and reactive oxygen and nitrogen species. Ex-
posure to LPS can inhibit neurogenesis [18] and exert
neurotoxic effects in vitro [14,19,20] and in vivo [21].
Conversely, alternative activation, often characterized by
increases in hallmark genes such as arginase 1 and the
mannose receptor C type 1 (MRC1/CD206), is thought
to help resolve acute inflammation by antagoni-
zing pro-inflammatory mediators, initiating repair and
reconstructing the ECM. Both IL4-stimulated macro-
phages and microglia generally produce less nitric oxide
and more L-proline and type 2 cytokines (for example,
IL10, transforming growth factor-β) that help promote
tissue repair [5,6]. There is evidence that IL4-treated
microglia promote neuroprotection [22,23], neurogen-
esis and oligodendrocyte genesis [24]. It is increasingly
recognized that responses of microglia to CNS injury are
more complex than M1 and M2 macrophage activation,
and are likely modulated by the type of injury, timing
and environment; possibly involving a continuum of
states [9,25].
Here, as in numerous papers, to model the two ex-
tremes of microglial activation in vitro, we use LPS to
induce classical activation and IL4 to induce alternative
activation. The purpose of this study was to analyze how
these activation states affect microglial migration, inva-
sion, and the enzymes used for ECM degradation
in vitro. We compared morphological hallmarks of mi-
grating cells (F-actin distribution, cellular adhesions,
orientation of the nuclear-centrosomal (NC) axis), and
quantified random migration, chemotaxis in response to
adenosine triphosphate (ATP), and invasion through
Matrigel™. Finally, we compared microglial expression of
nine matrix-degrading enzymes in three classes
(heparanase, matrix metalloproteases (MMPs), and ca-
thepsins), and used a panel of inhibitors to address their
contributions to invasion. Because microglia migrate
in vivo after many types of damage and disease, we ini-
tially expected that they would migrate and invade well,
regardless of their activation state. Instead, our results
show that microglial morphology, migration, invasion,
and matrix-degrading enzyme usage differed depending
on the activation state.
Materials and methods
Cell cultures
All procedures on animals were approved by the Univer-
sity Health Network Animal Care Committee, in accord-
ance with guidelines from the Canadian Council on
Animal Care. Our standard protocols [14,19,26] were
used to isolate and culture primary microglia from 1
to 2 day-old Sprague–Dawley rat pups (Charles River,
St.-Constant, PQ, Canada). Most importantly, these
methods produce ≥99% pure microglia, and greatly re-
duce their levels of spontaneous activation [16,27]. In
brief, after removing the meninges, the entire brain is
minced, centrifuged (300 ×g, 10 min), re-suspended in
Minimal Essential Medium (MEM; Invitrogen, Carlsbad,
CA, USA) with 10% fetal bovine serum (FBS; Wisent,
St-Bruno, PQ, Canada), and 0.05 mg/ml gentamycin
(Invitrogen), and seeded in tissue culture flasks. After 48
hr culturing at 37°C and 5% CO2, the cells were washed
and cultured with 2% FBS for 4 to 5 days. The flasks were
then shaken (2 to 4 hr, 65 rpm, 37°C, 5% CO2) and
microglia were harvested, washed and plated on sub-
strates and at densities appropriate for each assay.
Chemicals
Classical activation was evoked using 10 ng/ml LPS from
E. coli K-235 (Sigma-Aldrich, Oakville, ON, Canada), as
before [16,27]. Alternative activation was evoked with 20
ng/ml recombinant rat IL4 (R&D Systems Inc., Minne-
apolis, MN, USA), as before [27]. For the transmigration
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and invasion assays, microglia were treated 1 hr after
either stimulus with one of the following inhibitors.
The broad-spectrum MMP inhibitor, GM6001 (EMD
Millipore, Toronto, ON, Canada) has Ki values from 0.2
to 27 nM depending on the MMP, and the heparanase
inhibitor, OGT 2115 (R&D Systems) has an IC50 of 0.4
μM. The cysteine protease inhibitor, E-64 (Sigma), was
used to inhibit cysteine cathepsins (Cats), (IC50 = 1.4,
4.1, 2.5 nM for Cat K, S and L, respectively). The select-
ive Cat S inhibitor (Z-FL-COCHO; EMD Millipore) has
a Ki value of 185 pM, and the selective Cat K inhibitor I
(1,3-Bis(CBZ-Leu-NH)-2-propanone (EMD Millipore)
has a Ki of 22 nM. All inhibitory constants were
according to the suppliers. Stock solutions were made in
DMSO (GM6001, OGT2115, Cat inhibitors), sterile
double distilled water (LPS, E-64) or sterile phosphate
buffered saline (PBS) with 0.3% bovine serum albumin
(IL4). For all inhibitors, aliquots were stored at −20°C.
ATP was prepared just before use.
Quantitative real-time reverse transcriptase polymerase
chain reaction
To monitor gene transcript levels, 500,000 cells were
seeded into each 35 mm culture dish (Sarstedt Inc.,
Montreal, QC, Canada), and our standard protocol was
used, as recently described [16,27]. Gene-specific
primers (Table 1) were designed using ‘Primer3Output’
[28]. After 24 hr treatment with LPS or IL4, total RNA
was extracted from primary microglia using the TRIzol
method (Invitrogen), followed by RNeasy Mini Kit
(QIAGEN, Mississauga, ON, Canada) for further purifi-
cation. A two-step reaction was performed according to
the manufacturer’s instructions (Invitrogen). In brief,
total RNA (0.8 μg) was reverse transcribed in 20 μl
volume using 200 U of SuperScriptII RNase reverse
transcriptase, with 0.5 mM dNTPs and 0.5 μM oligo
dT (Invitrogen). Amplification was performed on an
ABI PRISM 7700 Sequence Detection System (PE
Biosystems, Foster City, CA, USA) at 95°C for 10 min,
40 cycles at 95°C for 15 s, and 56°C for 20 s. ‘No-tem-
plate’ and ‘no-amplification’ controls were included for
each gene, and melt curves showed a single peak,
confirming specific amplification. The threshold cycle
(CT) for each gene was determined, and normalized to
that of the housekeeping gene, hypoxanthine guanine
phosphoribosyl transferase (HPRT1), which we find to
be especially stable in primary rat microglia under all
treatments we have investigated [16,19,27]. Results are
Table 1 Primers used for qRT-PCR
Gene Genbank accession # Primer sequences
Cathepsin B NM_022597.2 FP: CCCTGTGAACACCATGTCAATG
RP: GATGTGGAGTAGCCAGCCTCAC
Cathepsin K NM_031560.2 FP: TGTGGGTGTTCAAGTTTTTGCTG
RP: GTACTGCTTCCCGTGGGTCTTC
Cathepsin L1 NM_013156.1 FP: ACCATGACCCCTTTACTCCTCCT
RP: CTCCTCCACTCTTCCTCATTCGT
Cathepsin S NM_017320.1 FP: CCATTCCTCCTTCTTCCTCTACCA
RP: CCATCAAGAGTCCCATAGCCAAC
Heparanase NM_022605.1 FP: GACGGACTGCTTTCCAAATCC
RP: CGGGGAGAGGTTTTTCTGTTAGAG
HPRT1 XM_343829 FP: CAGTACAGCCCCAAAATGGT
RP: CAAGGGCATATCCAACAACA
MMP2 NM_031054.2 FP: TCTCCCCCAAAACAGACAAAGAG
RP: TCCTTCAGCACAAAGAGGTTGC
MMP9 NM_031055 FP: CTGCCTGCACCACTAAAGG
RP: GAAGACGAAGGGGAAGACG
MMP12 NM_053963 FP: CTGGGCAACTGGACACCT
RP: CTACATCCGCACGCTTCA
MMP14 NM_031056.1 FP: GTTCTGGCGGGTGAGGAATAAC
RP: TCATAGGCAGTGTTGATGGATGC
TIMP-1 NM_053819 FP: GGTTCCCCAGAAATCATCG
RP: GGAAACCTGTGGCATTTCC
FP forward primer, RP reverse primer.
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expressed as relative mRNA expression (mean ± SEM)
from four separate microglia cultures grown from four
different rat pups.
Immunocytochemical analysis
The methods were similar to our recent paper [29].
Microglia were seeded at 60,000 cells per UV-irradiated
15 mm glass coverslip (Fisher Scientific, Ottawa, ON,
Canada). They were cultured for 1 day in MEM with 2%
FBS, and then fixed in 4% paraformaldehyde (Electron
Microscopy Sciences, Hatfield, PA, USA) at room
temperature for 15 min. Cells were permeabilized with
0.2% Triton X-100 for 5 min and washed in PBS (3×, 5
min each). Non-specific binding was blocked with 4%
donkey serum for 1 hr. All antibodies were diluted in
2.5% donkey serum and centrifuged before use (8200 ×g,
10 min) to precipitate aggregated antibody, if present.
Microglia were incubated with a primary antibody over-
night at 4°C: mouse monoclonal anti-vinculin (1:200;
Sigma) or mouse monoclonal anti-α tubulin (1:1000;
Abcam, Cambridge, MA, USA). Cells were washed (3×,
5 min each), blocked with 5% donkey serum for 1 hr, in-
cubated with a corresponding donkey secondary anti-
body (1:200, Jackson Immunoresearch, West Grove, PA,
USA) for 1 hr, and then washed (3×, 10 min each).
Negative controls were prepared using the same proto-
col, but omitting primary antibody. Filamentous (F-)
actin was visualized by incubating cells (15 min, room
temperature) with Alexa Fluor 488-conjugated phal-
loidin (Invitrogen) at 1:50 in blocking solution. Cell nu-
clei were labeled with 4′,6-diamidino-2-phenylindole
(DAPI; 1:3000 in PBS, 5 min; Invitrogen). After washing
(3×, 5 min each), cells on coverslips were mounted on
glass slides with Dako mounting medium (Dako,
Glostrup, Denmark) and stored at 4°C. Microglia were
sometimes labeled with FITC-conjugated tomato lectin
(TL; 1:500, 15 min; Sigma), which binds to N-acetyl-
lactosamine residues on the microglia surface.
Differential interference contrast (DIC) images were
acquired with a Zeiss Axiovert 200 M microscope
equipped with an ORCA-ER camera (Hamamatsu Cor-
poration, Bridgewater, NJ, USA). All other images were
acquired with either an LSM 510 META laser scanning
confocal microscope or an Axioplan 2 widefield epifluor-
escence microscope equipped with an Axiocam HRm
digital camera, and were analyzed with Axiovision 4.6
software (all from Carl Zeiss, Jena, Germany) or with
ImageJ [30]. For many images, we acquired Z-stacks
through the entire cell from high magnification epifluor-
escence images recorded at 200 nm increments. These
images were then deconvolved using either Axiovision
software with correction for Dako Fluorescent Mounting
Medium or AutoQuant X software (version 2.2.2, Media
Cybernetics Inc, Bethesda, MD, USA) using a theoretical
point spread function and the constrained iterative algo-
rithm. When constructing Z-stacks, the automated
correction algorithm was used to compensate for fluor-
escence decay during repeated exposures. Cell auto-
fluorescence and non-specific staining were monitored
on cells exposed to secondary antibodies alone, with the
same imaging and acquisition settings. This background
was subtracted.
Migration, substrate degradation and invasion assays
For the scratch wound assay, 80,000 cells were seeded
onto each UV-irradiated 15 mm glass coverslip (Fisher
Scientific) in 12-well plates. For transmigration and inva-
sion assays, 30,000 cells were seeded onto each
Transwell™ filter insert (VWR, Mississauga, ON,
Canada). These methods are essentially the same as our
recent papers [26,29], and will be stated only briefly
here.
Scratch wound migration assay
One hour after plating the microglia, the standard
medium (MEM with 2% FBS) was added. One hour later,
LPS (10 ng/ml) or IL4 (20 ng/ml) was added. The cells
were cultured for approximately 18 hr, at which time
they were approximately 80% confluent. The monolayer
was scratched with a sterile 200 μl pipette tip, and the
cells were incubated for a further 24 hr to allow time for
migration into the cell-free area. We counted all micro-
glia in the scratch region and calculated the mean from
five separate cultures.
Transmigration analysis
Microglia were suspended in standard medium, and 30,000
cells were added to the upper well of each Transwell™ insert
(VWR), which bore an uncoated filter with 8 μm diameter
holes. The lower well contained only medium. After 1 hr,
microglia were incubated for 24 hr (37°C, 5% CO2) with ei-
ther 10 ng/ml LPS or 20 ng/ml IL4. For the chemotaxis
assay, 300 μM ATP (Sigma) was added to the lower well 1
hr after the addition of LPS or IL4. The cell-bearing filters
were fixed in 4% paraformaldehyde for 10 min, rinsed with
PBS, and the microglial cells remaining on the upper side of
each filter were removed with a Q-tip. The filters were then
stained with 0.3% crystal violet for 1 min, and again rinsed
with PBS. The number of cells that had migrated to the
underside was counted (5 random fields/filter) at 20× mag-
nification using an Olympus CK2 inverted microscope
(Olympus, Tokyo, Japan).
Fibronectin substrate degradation
A standard assay for degradation of ECM employs
fluorescent-labeled substrate (usually fibronectin or
gelatin) on glass coverslips. ECM degradation is then mon-
itored as loss of the substrate fluorescence. We coated
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Figure 1 (See legend on next page.)
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coverslips with HiLyte Fluor™ 488-labeled fibronectin
(Cytoskeleton Inc., Denver, CO, USA) in PBS (2 μg/ml;
150 μl/coverslip). After 2 to 3 hr at 37°C, the fibronectin
solution was aspirated off, microglia were added (50,000
cells/coverslip) and allowed to settle for 1 hr. Standard
medium was added, followed 1 hr later by LPS (10 ng/ml)
or IL4 (20 ng/ml). After a 24-hr incubation (37°C, 5%
CO2), the cells were fixed and visualized using
an Axioplan 2 widefield epifluorescence microscope
equipped with an Axiocam HRm digital camera.
Invasion analysis
Microglial invasion was examined using BioCoat
Matrigel™ Invasion Chambers (BD Biosciences, Missis-
sauga, ON, Canada). These are similar to Transwell™
chambers, except that the 8 μm diameter holes in the
upper filter are coated with Matrigel™, which is a base-
ment membrane-type of ECM secreted by mouse sar-
coma cells. Microglia in fresh standard medium
(control) were added to the upper well (30,000/filter).
After 1 hr incubation (37°C, 5% CO2), 10 ng/ml LPS or
20 ng/ml IL4 was added to the experimental wells.
When used to stimulate chemotaxis, 300 μM ATP was
added to the lower chamber of wells after another 1 hr
incubation. All chambers were then incubated for 24 hr
(37°C, 5% CO2).
Statistical analysis
Quantitative data are presented as mean ± SEM, and an-
alyzed with either one-way analysis of variance
(ANOVA), followed by Tukey’s post-hoc test or two-way
ANOVA with Bonferroni correction. GraphPad Prism
ver 5.01 (GraphPad Software, San Diego, CA) was used.
Results are considered significant if P <0.05.
Results
The microglial activation state affects their morphology
In order to analyze functional outcomes of different acti-
vation stimuli, we have established culturing methods
that maintain a relatively resting state with low produc-
tion of cytokines and reactive oxygen and nitrogen
species [14,16,27]. Here, untreated primary rat microglia
had very low expression of the three activation markers:
inducible nitric oxide synthase (iNOS), IL1β, mannose
receptor 1 (MRC1/CD206). LPS selectively induced the
classical activation markers, iNOS and IL1β, while IL4
selectively induced the alternative-activation marker,
MRC1 (Figure 1A), as before [11]. We have used LPS ex-
tensively to investigate microglial responses that include
gene expression [27], phagocytosis [16], and neurotoxic
capacity [19], and have even compared different bacterial
strains as sources of LPS [16]. Our experience is that 10
ng/ml LPS from E. coli strain K-235, as used here, is op-
timal for neonatal rat microglia, and induces numerous
genes (for example, IL1β, TNFα, and iNOS) and func-
tional responses (for example, NFκB and p38 MAPK ac-
tivation, phagocytosis, and neurotoxicity) that are typical
of a pro-inflammatory state. We chose the concentration
of 20 ng/ml recombinant rat IL4 based on recent studies
from our lab and others that found induction of well-
known alternative activation markers [23,27] and
neuroprotection [23].
The activation stimuli differentially affected the micro-
glia morphology. Most untreated cells were unipolar,
with a fan-shaped lamellum and one or more long pro-
cesses (Figure 1B, C). A minority of cells was bipolar
(Figure 1B, arrowhead). We previously showed that uni-
polar microglia are migrating in the direction of the
lamellum and bipolar cells are not migrating, but micro-
glia readily transition between migrating and non-
migrating phenotypes [29]. Although the morphology
was more variable after IL4 treatment, many cells were
unipolar with a lamellum that was generally smaller than
in control microglia (Figure 1B), and they exhibited ex-
tensive ruffling (Figure 1C, open arrows). After LPS
treatment, most microglia were amoeboid shaped
(Figure 1B) or round and flat (for example, Figure 1C,
cell in center). Vinculin and F-actin staining were used
to monitor the underlying cytoskeleton in deconvolved
high-magnification fluorescent images (Figure 1D). Con-
trol cells had punctate vinculin and F-actin staining
throughout the cell body and lamellum, with extensive
(See figure on previous page.)
Figure 1 The activation state affects microglial morphology. A) Increased expression of molecules that are hallmarks of classical activation
(iNOS, IL1β) and alternative activation (MRC1/CD206). Rat primary microglial cells were stimulated for 24 hr with 10 ng/ml lipopolysaccharide
(LPS) or 20 ng/ml rat recombinant IL4. Gene expression was monitored by quantitative reverse transcriptase (RT)-PCR and normalized to the
housekeeping gene, HPRT1. Values are expressed as mean ± SEM for four replicates using different cell cultures. One-way ANOVA with Tukey’s
post-hoc test revealed differences from control microglia: ***P <0.001. B) Fluorescence micrographs show that the microglial morphology
changes following stimulation with LPS or IL4. Fixed cells were stained with the microglia marker, tomato lectin (FITC-conjugated; green), and
nuclei were visualized with DAPI (blue). Examples of unipolar microglia with a fan-shaped lamellum are indicated by arrows, and a bipolar cell is
shown by the arrowhead. (Note the 100% purity of the microglial cultures.) Scale bar, 50 μm. C) Differential interference contrast (DIC)
micrographs of microglia. For control, untreated microglia, the arrows indicate the smooth leading edge of the lamellum. For IL4-treated cells, the
open arrows show regions of membrane ruffling. Scale bar, 50 μm. D) Higher-magnification deconvolved fluorescent images of microglia. The
fluorescent labels show F-actin (stained with phalloidin, green), the actin-binding protein, vinculin (red), and cell nuclei (DAPI, blue). The boxed
areas were digitally magnified (4×) and shown as insets. Scale bars, 20 μm (main images), 5 μm (insets).
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co-localization in fine processes toward the trailing end
(see insets). In IL4-treated cells, the vinculin and F-actin
co-labeling was especially intense in the ruffles at the
leading edge (open arrow) and in the uropod. LPS-
treated microglia had short, fine vinculin- and F-actin-
rich processes (inset) that lacked preferential orientation
around the cell.
Polarization of nuclear-centrosomal axis depends on the
microglial activation state
When migrating on two-dimensional surfaces, many cell
types (including macrophages), reorient the microtubule
network toward the leading edge, so that the micro-
tubule organizing center (MTOC) is anterior to the nu-
cleus (see Discussion). As expected, in unipolar
Figure 2 Repolarization of the axis of the microtubule organizing center (MTOC) and nuclear centrosomal (NC) axis depends on the
microglial activation state. Rat microglia were stimulated for 24 hr with 10 ng/ml lipopolysaccharide (LPS) or 20 ng/ml rat recombinant IL4. A)
Confocal images of microglia labeled for α-tubulin (red) to visualize microtubules and the MTOC, and DAPI (blue) to label nuclei. F-actin was
labeled with Alexa Fluor 488-conjugated phalloidin (green) to reveal the cell shape. In unipolar microglia, the MTOC was in one of three peri-
nuclear orientations (and see cartoon in panel B): toward the leading edge (arrows), at the side (open arrow) or toward the uropod (arrowheads).
Higher magnification images (bottom panel) show the anterior and posterior positions, and the lack of microtubule polarization in LPS-treated
cells. Scale bars, 20 μm. B) Quantification of MTOC-nuclear orientation. Only unipolar (migrating) microglia were analyzed: that is, control and IL4-
treated cells. For each slide, ten random images were acquired at 10× magnification on the confocal microscope. MTOC orientation was scored
based on its peri-nuclear position (cartoon inset): anterior (MTOC toward leading edge), posterior (MTOC toward uropod), lateral (MTOC at side).
For each treatment replicate, ≥90 unipolar microglia were scored. Results are expressed as percent of total cells counted (mean ± SEM, n = 7
individual cultures). Two-way ANOVA with Bonferroni correction revealed significant intergroup differences: ***control differs from IL4-treated;
###MTOC position differs from anterior position of control cells. Three symbols indicate P <0.001.
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untreated microglia, the microtubules (labeled for α-
tubulin) were dense near the nucleus, radiated toward
the lamellum and fanned out, and were tightly bundled
down the uropod (Figure 2A). A similar pattern was
seen in unipolar IL4-treated cells. In contrast, the
microtubule distribution in LPS-treated cells was less
polarized, and they radiated toward the plasma mem-
brane in multiple directions. We quantified the MTOC
orientation in unipolar control and IL4-treated microglia
with a prominent lamellum and a trailing uropod
(Figure 2B). [LPS-treated cells were omitted because they
did not display this morphology.] The cartoon illustrates
the peri-nuclear MTOC positions: anterior, posterior, and
lateral. Two scorers (one blinded to the treatments) inde-
pendently quantified the data and obtained the same
results. That is, under control conditions, the NC axis
Figure 3 Migration and chemotaxis are affected by the microglial activation state. Cells were untreated (control) or exposed to 10 ng/ml
lipopolysaccharide (LPS) or 20 ng/ml IL4. A) Migration into a scratch wound in a monolayer of microglia. Cells were fixed and stained after 24 hr
with the microglial marker, FITC-conjugated tomato lectin (green), and the nuclear marker, DAPI (blue). Scale bar, 100 μm. A′) For each slide,
confocal images of five random fields were taken along the border of the scratch (delineated by dashed red lines), and all lectin-positive cells
within the scratch region were counted. B) Transmigration of microglia in Transwell™ chambers. After each 24-hr treatment, cells that had
migrated to the underside of each filter were counted in five random fields. C) Chemotactic response to 300 μM ATP added to the lower
Transwell™ chamber (striped bars) compared with unstimulated transmigration (solid bars). Results were analyzed as in panel B, and then
normalized to control transmigration without ATP. Results are reported as mean ± SEM, with the number of individual cultures indicated on each
bar. Statistical differences were determined using either one-way ANOVA with Tukey’s post-hoc test (A, B) or two-way ANOVA with Bonferroni
post-hoc test (C). # indicates an effect of ATP; * (A, B) or † (C) indicates treatment differences (control versus LPS or IL4). One symbol, P <0.05; two
symbols, P <0.01; three symbols, P <0.001.
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had reoriented in 77% of unipolar microglia to position
the MTOC anterior to the nucleus, and only 3% of cells
showed a posterior orientation. In striking contrast, in
IL4-treated microglia, there was an equal likelihood of
each of the three orientations.
Migration, chemotaxis and invasion depend on the
microglial activation state
Based on the observed differences in morphology and
MTOC polarization (Figures 1 and 2), we hypothesized that
the activation state will alter directional microglial migration.
First, a scratch wound assay was used to analyze migration
in 2-D while viewing the cell morphology (Figure 3A). Both
untreated (control) and IL4-treated microglia migrated into
the cell-free area but the response of IL4-treated cells was
nearly 2-fold higher. Very few LPS-treated microglia mi-
grated into the scratch wound (approximately 30% of the
control value). Next, migration in 3-D was quantified using
the Transwell™ chambers (Figure 3B). Significantly more
IL4-treated microglia transmigrated than control cells (2.3-
fold increase); whereas, LPS-treated cells migrated very little
(24% of the control value). In all cases, transmigration was
increased by a gradient of the chemoattractant, ATP
(Figure 3C): that is, by 5.9-fold (control), 4.4-fold (IL-4-
treated), and 7.3-fold (LPS-treated). Nevertheless, chemo-
taxis of IL4-treated cells remained the highest: 74% higher
than control cells, 7-fold higher than LPS-treated cells.
We recently showed that unstimulated microglia can
degrade fibronectin [26,29]. In the absence of microglia,
the substrate fluorescence was uniform (Figure 4A). Re-
gardless of treatment, microglial cells degraded fibronec-
tin, leaving cell-sized patches of reduced fluorescence.
The invasion capacity of microglia was then analyzed
using an assay in which migration to the underside of
each filter requires degradation of Matrigel™. IL4-treated
microglia invaded 1.7-fold more than control cells;
whereas, LPS-treated cells invaded 66% less (Figure 4B).
Adding ATP to the lower well increased the invasiveness
of unstimulated cells by 2.6 fold, and IL4-treated cells by
3.2 fold (Figure 3C). IL4-treated microglia had a 2.2 fold
Figure 4 The microglial activation state affects invasion through the extracellular matrix (ECM). A) Microglia were plated on glass
coverslips coated with fluorescent-labeled fibronectin, without (control) or after 10 ng/ml lipopolysaccharide (LPS) or 20 ng/ml IL4 treatment.
The corresponding phase contrast images show cell locations and morphology. Scale bar, 20 μm. B) Microglia invasion through Matrigel™-coated
8 μm diameter holes in Transwell™ chambers. For each treatment, cells that had invaded to the underside of the filter after 24 hr were visualized
and counted as in Figure 3B. Results are expressed as mean ± SEM for the number of individual cell cultures indicated on each bar. *P <0.05;
**P <0.01. C) Chemotactic invasion. Either medium alone (solid bars) or the chemoattractant, 300 μM ATP (striped bars), was added to the lower
well of the Transwell™ chamber. After 24 hr, cells were counted as in Figure 3C. Results were normalized to control invasion without ATP and
reported as mean ± SEM for the number of individual cultures indicated. Statistical differences were determined using two-way ANOVA, followed
by Bonferroni post-hoc tests. ### indicates effect of ATP; ††† indicates a difference between control and IL4-treatment. P <0.001.
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greater invasion capacity than unstimulated cells. LPS-
treated cells were not analyzed because they migrated
and invaded very poorly.
IL4-treated microglia use a wide range of degradative
enzymes for invasion
Degradation of ECM can involve any or all of three
broad classes of degradative enzymes: MMPs, cathep-
sins, and heparanase. To analyze their contributions
to microglia transmigration and invasion, we first
used three class-specific but broad-spectrum inhibi-
tors: GM6001 (MMPs), E-64 (cysteine proteases, in-
cluding Cat B, K, L1 and S), OGT2115 (heparanase).
Then, based on the results, we tested selective inhibi-
tors of Cat S (Z-FL-COCHO) or Cat K (1,3-Bis(CBZ-
Leu-NH)-2-propanone). For each inhibitor, we used a
single concentration. Because the invasion assay was
for 24 hr, during which the inhibitor efficacy might
decrease, for the broad-spectrum inhibitors, we chose
a high concentration in an attempt to inhibit all the
subtypes within the relevant enzyme class. Then, for
the selective Cat S and Cat K inhibitors we used a
concentration that was 10 to 20 times the IC50, which
is expected to inhibit >90% of the enzyme activity.
Importantly, none of the inhibitors was toxic at con-
centrations and times used. For control, unstimulated
microglia, none of the enzyme inhibitors affected trans-
migration through open holes in the filter (Figure 5A),
which also demonstrates lack of non-specific effects
or toxicity.
Only IL4-treated microglia were compared with
controls because LPS-treated cells migrated very
poorly (Figures 3 and 4B). IL4 treatment greatly in-
creased transmigration, and this was reduced back to
the control level by the Cat S inhibitor. The apparent
trend toward reduced transmigration by three other
inhibitors did not reach statistical significance with
the sample size used. None of the inhibitors affected
cell viability at the concentrations and times tested.
Interestingly, invasion through the same ECM sub-
strate (Matrigel™) required different enzymes in un-
treated and IL4-treated microglia. In unstimulated
microglia, invasion was inhibited only by the broad-
spectrum cysteine cathepsin inhibitor, E-64, which
decreased invasion to approximately 50% below the
control level (Figure 5B). Invasion was not altered by
the selective Cat S and K inhibitors, suggesting that
E-64 acts through a different enzyme. IL4 treatment
increased invasion about 2-fold, and all the enzyme
inhibitors then reduced it to the baseline level. These
results demonstrate that IL4-treated microglia can use
all three classes of ECM-degrading enzymes for inva-
sion. Untreated microglia were more restricted, using
primarily cysteine cathepsins.
The microglial activation state alters expression of ECM-
degrading enzymes
Based on the differences in migration and enzymes used for
invasion in unstimulated versus IL4-treated microglia, we
next compared transcript expression of several ECM-
degrading enzymes (Figure 6). LPS-treated cells were also
examined because they degraded fibronectin (Figure 4)
despite being poorly migratory (Figure 3). For eight of the
nine enzymes examined, the pattern was unique to
the stimulus (there was no change in Cat B). LPS-
treated microglia had increased MMP9, MMP12, MMP14
(MT1-MMP), heparanase and Cat L1. In IL4-treated micro-
glia only MMP2, Cat S and Cat K increased (Figure 6),
which is consistent with the unique contribution of Cat S
and Cat K to invasion in IL4-treated cells (Figure 5). Given
the small increase in MMP2 only, and the increase in the
general MMP-inhibitor, TIMP metallopeptidase inhibitor 1
(TIMP1), we were surprised that invasion by IL4-treated
Figure 5 Contributions of extracellular matrix (ECM)-degrading
enzymes. The enzyme inhibitors included three class-specific but
broad-spectrum inhibitors: 5 μM GM6001 to inhibit MMPs, 5 μM
OGT 2115 to inhibit heparanase, and the cysteine protease inhibitor,
10 μM E-64, which also inhibits cysteine cathepsins, including Cat B,
K, L1 and S. The selective cathepsin inhibitors were: 5 nM Z-FL-
COCHO to inhibit Cat S, and 250 nM 1,3-Bis(CBZ-Leu-NH)-2-
propanone, also called Cat K inhibitor I. Microglia were untreated or
exposed to 20 ng/ml IL4 for 24 hr. A) Transmigration through open
8-μm diameter holes in the filters of Transwell™ chambers.
B) Invasion through Matrigel™-coated 8-μm diameter holes. *IL4-treated
differ from control cells; #differs from untreated cells; †differs from
IL4 alone. Two symbols, P <0.01; three symbols, P <0.001.
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cells was reduced by the broad-spectrum MMP inhibitor,
GM6001.
Discussion
We report the novel finding that IL4-treated, alterna-
tively activated rat microglia have an increased migratory
capacity in both 2-D (scratch wound) and 3-D
(Transwell™) assays. We found that LPS-treated micro-
glia were less migratory. Previous reports are inconsist-
ent, and while the reasons are not clear, the effect of
LPS on migration might depend on species and strain,
cell type and age. Impaired migration has been reported
for neonatal rat [31] and adult human microglia [32],
and for guinea pig peritoneal macrophages [33] and
rabbit alveolar macrophages [34]. Conversely, some
studies reported that LPS can increase migration in the
RAW264.7 macrophage cell line [35,36] and primary rat
peritoneal macrophages, but the LPS dose was not stated
[35]. Interestingly, migration of peritoneal macrophages
was mildly inhibited by LPS in LPS-sensitive mouse
strains (C3H/HeN, C57BL10/S) but increased in LPS-
resistant mice (C3H/HeJ, C57BLlO/ScCR strains), al-
though only at LPS doses greater than 50 ng/ml [37].
The effect of microglia age is also unknown; the rat
microglia studies used neonates (present study; [31]),
while the macrophage studies used adult animals. An-
other difficulty in comparing results is the differing con-
centrations and strains of LPS used but an earlier dosing
study found that the same concentration (10 ng/ml) re-
duced migration of primary guinea pig peritoneal macro-
phages by 56% [33].
After acute CNS injury, damaged cells can release
ATP, glutamate and nitric oxide, which can attract
microglial processes [1] and recruit them to damage
sites [2]. In all of our assays, ATP increased microglia
migration, whether the cells were untreated or stimu-
lated with IL4 or LPS. While this shows that microglia
can respond to ATP regardless of their activation state,
IL4-treated microglia remained the most migratory and
LPS-treated cells the least migratory. In the damaged
brain, additional stimuli and chemotactic factors (for
example, chemokines and matricellular molecules) will
be present and that their effects on migration patterns
of activated microglia might be complex.
The migratory phenotype is established by interactions
between a cell and substrate [38] and is often analyzed
as 2-D migration on glass. The lamellum adheres to the
ECM, provides a broad surface for traction, and contains
a network of actin filaments, like that seen in untreated
rat microglia. We found that the morphology and
cytoskeletal arrangement of microglia was profoundly
affected by LPS, and more subtly affected by IL4. LPS-
treated cells were ameboid or rounded up, and had
many vinculin-rich and F-actin-rich filopodia without a
specific orientation. This is consistent with previous
descriptions of LPS-activated microglia [39,40]. In con-
trast, most resting and IL4-treated microglia had a pola-
rized morphology, with a lamellum at the front and a
uropod at the rear. In earlier work, IL4 changed rat [41]
and mouse [42] primary microglia from rounded or
Figure 6 Expression of extracellular matrix (ECM)-degrading
enzymes. Gene expression was monitored by quantitative reverse
transcriptase (RT)-PCR and normalized to the housekeeping gene,
Hprt1. (Note the different Y-axis scales.) The values are expressed as
mean ± SEM, with the number of individual cultures indicated on
each bar. The genes are: Mmp2, Mmp9, Mmp12, Mmp14, Timp1,
heparanase, Cat B, Cat L1, Cat S, Cat K. One-way ANOVA with Tukey’s
post-hoc test revealed differences from control microglia: *P <0.05,
**P <0.01, ***P <0.001.
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ameboid to a more ramified shape, with processes and la-
mellipodia. However, we found that the lamellum of IL4-
treated cells was smaller and exhibited more membrane
ruffles, and both the lamellum and uropod showed ex-
tensive co-localization of F-actin and vinculin. Changes
in actin distribution and polymerization underlie the
morphological polarization and roles of both the
lamellum and the uropod [4]. Precise roles of the uropod
in cell migration are unknown but it is considered im-
portant for cells that migrate through tight spaces
[38,43]. The presence of a uropod and lamellum in rest-
ing and alternatively activated microglia suggests that
these cells will migrate well through the tightly packed
brain parenchyma during development and after CNS
injury.
A hallmark of polarization in migrating cells is coordi-
nated reorientation of the NC axis [44]. In many migra-
ting cells, the nucleus moves toward the rear, resulting
in an ‘anterior’ NC axis in which microtubules oriented
toward the leading edge are stabilized. The MTOC,
endoplasmic reticulum and Golgi apparatus are then in
front of the nucleus. Many cells display an anterior NC
orientation when migrating on 2-D substrates: for ex-
ample, macrophages, neurons, astrocytes, and epithelial
and mesenchymal cells [44]. The opposite ‘posterior’ NC
orientation (nucleus in front of MTOC) is less common
but seen in some migrating immune cells, especially
neutrophils [45] and T lymphocytes [44]. The precise
role of the MTOC position in cell migration is unknown;
however, it can be affected by extracellular cues. For in-
stance, neutrophils changed their MTOC orientation to
an anterior position during chemotaxis [46], and to a
dorsal position near the cell surface after exposure to an
antigen-antibody complex [47]. MTOC repositioning
during non-migratory events includes re-orientation to-
ward phagosomes in macrophages [48] and toward the
immune synapse in bone-derived dendritic cells [49].
Neutrophils are especially interesting because they are
one of the fastest moving mammalian cells [50], and ex-
hibit a variable MTOC orientation during random mi-
gration on glass [45] or formvar (a support film for
electron microscopy) [46]. We found that the MTOC in
untreated microglia was polarized toward the leading
edge; whereas, the highly migratory IL4-treated cells
lacked this preferential MTOC/NC orientation. IL4-
treated microglia also had a smaller lamellum than con-
trol cells, with extensive membrane ruffling that is
consistent with reduced adhesion. LPS-treated microglia
were much less migratory, lacked a lamellum and uro-
pod and had many filopodia, suggesting that they adhere
more tightly to the substrate.
Cell invasion requires migration and substrate degra-
dation. Specifically, in order to navigate the tightly packed
brain parenchyma in vivo, microglia need to cleave cell-
substrate interactions and degrade the ECM. Given the
dramatic changes in microglial migration evoked under
different activation conditions, it was important to deter-
mine if cell invasion was affected, and if so, whether the
expression and roles of specific matrix-degrading enzymes
were altered. We observed that rat microglia could de-
grade fibronectin regardless of their activation state but
their ability to invade through Matrigel™ differed dramati-
cally. IL4-treated microglia invaded more than untreated
cells, and LPS-treated microglia invaded less. While dif-
ferences in their migratory capacity contribute, this can-
not account for the different matrix-degrading enzymes
used for invasion by untreated versus IL4-treated micro-
glia. Migration of untreated microglia on 2-D substrates
did not require any of the enzymes tested. In contrast,
IL4-treated cells used a broad range of enzymes for migra-
tion and especially for invasion through ECM. Importantly,
in untreated microglia, we found that the heparanase in-
hibitor reduced invasion through Matrigel™, which
supports a role for heparanase in ECM degradation.
This is consistent with a study reporting that hepa-
ranase is involved in invasion of untreated microglia
[51]. In that study, LPS evoked an increase in the ac-
tive heparanase isoform and degradation of heparan
sulfate proteoglycans.
Expression of almost all matrix-degrading enzymes ex-
amined differed with the microglial activation state.
There are previous reports that microglia express
heparanase, as well as several MMPs and cathepsins
[52]. Little is known about how LPS alters their expres-
sion, and almost nothing is known about the effect of
IL4. We found that IL4 treatment uniquely upregulated
several constitutively expressed enzymes: MMP2, Cat K,
Cat S, and the MMP inhibitor, TIMP1. LPS uniquely up-
regulated MMP9, MMP12, MMP14 (MT1-MMP),
heparanase and Cat L1, but did not alter MMP2, TIMP1
or Cat -B, -K or -S. Previously, LPS was seen to increase
expression of MMP12 and MMP14 in human microglia
[52], and MMP9 and MMP14 in murine microglia [53].
Given the broad range of enzymes expressed by LPS-
treated cells, their poor invasion capacity was likely due
to the lack of migration capacity.
It is an intriguing finding that microglia expressed and
used different cathepsins for migration and invasion: es-
pecially Cat S in IL4-treated cells. Most cysteine cathep-
sins are lysosomal endopeptidases that are active only at
acidic pH but Cat S is enzymatically active at both acidic
and neutral pH [54] and can degrade some ECM
components of the CNS [55]. Some cathepsins are ubi-
quitously expressed (Cat B, Cat L) and others are more
cell-specific (Cat K in osteoclasts) [56]. Cat S is thought
to be restricted to antigen-presenting cells [57] and can
be secreted by macrophages and microglia [54,58]. Cat S
is expressed in unstimulated microglia (present study)
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and is induced in microglia following spinal cord injury,
where it contributes to neuropathic pain [57]. There are
several previous studies of microglia activation and Cat
S but the results are inconsistent, and information relat-
ing it to IL4 treatment is very limited. IL4 increased the
Cat S activity in tumor-associated macrophages [59],
and we found it selectively upregulated Cat S (and Cat
K) expression. Cat S was involved in microglial migra-
tion and invasion; whereas, Cat K was only needed for
substrate degradation and invasion, consistent with its
essential role in bone resorption by osteoclasts [60].
After LPS treatment of primary rat microglia, we saw no
change in Cat S expression. Several studies have used
microglia cell lines, and this might account for the dis-
crepancies seen. Using the murine N-13 microglial cell
line, one study reported that LPS decreased Cat S cellu-
lar levels and activity but increased its secretion [58],
and another showed that basic fibroblast growth factor
increased both intra- and extracellular Cat S activity
[54]. In the BV-2 microglia cell line, LPS increased intra-
cellular levels of Cat S and Cat X but evoked secretion
of Cat -B, -K, -S and -X [61]. Interestingly, co-
stimulation of the P2X7 purinergic receptor was neces-
sary for secretion of enzymatically active Cat S from
LPS-treated rat primary microglia [62]. While there is
limited information about the roles of Cat S in vivo;
based on its actions on T cell polarization, Cat S inhibi-
tors are being considered for use in autoimmune
diseases [63].
Conclusions
Microglia migrate during normal CNS development and
after disease or damage in the adult. Their functional
roles will depend on their activation state, which itself is
modulated by complex environmental cues. Classical
and alternative activation states have been identified for
microglia (and macrophages) and are associated with
generally damaging and reparative functions, respect-
ively. Regardless of their activation state, microglia must
migrate and degrade the dense ECM to reach their tar-
get site. Thus, it is significant that classically and alterna-
tively activated microglial cells differed in their capacity
for migration and invasion, and in levels and usage of
several matrix-degrading enzymes in vitro. These diffe-
rences might determine how well they reach target sites,
and by providing specificity in matrix degradation, po-
tentially reduce bystander damage to the healthy ECM.
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